Markets:

Overview

News

Currencies

International

Treasuries

BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

0.2504 -0.0065 (-2.53%)

Streaming Delayed Price Updated: 11:37 AM EDT, Apr 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioRestorative Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results ↗

February 03, 2023

Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...

Via Benzinga

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies

January 26, 2023

By Faith Ashmore, Benzinga

Via TheNewswire.com

Topics Intellectual Property

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies

January 26, 2023

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies

Via News Direct

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies ↗

January 25, 2023

BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development.

Via Benzinga

BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication

December 06, 2022

From BioRestorative Therapies, Inc

Via GlobeNewswire

EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome ↗

December 06, 2022

BioRestorative Therapies Inc (NASDAQ: BRTX) has received a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development...

Via Benzinga

BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

December 05, 2022

From BioRestorative Therapies, Inc

Via GlobeNewswire

EXCLUSIVE: BioRestorative Therapies Gets Exclusive License Rights From Regenexx For Development Of BRTX-100 Disc Program To Treat Chronic Lumbar Disc Disease ↗

December 05, 2022

BioRestorative Therapies, Inc (NASDAQ: BRTX), a stem cell-based therapies clinical-stage company, forged an agreement with Regenexx, LLC, under which BRTX gets exclusive license rights for intellectual...

Via Benzinga

BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference

November 29, 2022

Via Investor Brand Network

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 23, 2022

Via Benzinga

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

November 16, 2022

From BioRestorative Therapies, Inc

Via GlobeNewswire

Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

November 15, 2022

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

Via FinancialNewsMedia

The NIH Has Given BioRestorative Therapies A Stamp Of Approval

November 10, 2022

By Faith Ashmore, Benzinga

Via News Direct

The NIH Has Given BioRestorative Therapies A Stamp Of Approval

November 10, 2022

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.

Via TheNewswire.com

The NIH Has Given BioRestorative Therapies A Stamp Of Approval ↗

November 09, 2022

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.

Via Benzinga

See What's Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies! ↗

October 28, 2022

While stem cell therapy has always been a more controversial topic, as the general public has gained more knowledge on the practice and induced pluripotent stem (iPS) cells have gained traction in...

Via Benzinga

BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show

October 20, 2022

From BioRestorative Therapies, Inc

Via GlobeNewswire

A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field

October 14, 2022

Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.

Via TheNewswire.com

A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field

October 14, 2022

By David Willey, Benzinga

Via News Direct

A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field ↗

October 13, 2022

Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.

Via Benzinga

Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday ↗

September 30, 2022

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.

Via Benzinga

Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday's Mid-Day Session ↗

September 29, 2022

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares jumped 52% to $2.1325 after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022 ↗

September 28, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 28, 2022

Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million.

Via Benzinga

BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference

September 28, 2022

From BioRestorative Therapies, Inc

Via GlobeNewswire

Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst

September 01, 2022

By Paul Henley, Benzinga

Via News Direct

Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst

September 01, 2022

In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. That’s why BioRestorative...

Via TheNewswire.com

Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst ↗

August 31, 2022

In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion.

Via Benzinga

EXCLUSIVE: BioRestorative Therapies Adds Additional Sites For Lumbar Disc Disease Trial ↗

August 24, 2022

BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into agreements with Vantage Clinical Trials LLC for its Phase 2 trial targeting chronic lumbar disc disease (cLDD).

Via Benzinga

Giving Metabolism A Boost? BioRestorative Uses Science Surrounding Brown Fat Cells To Provide A Possible Breakthrough In Metabolic Disorders ↗

August 23, 2022

In 2017, 41.9% of Americans experienced some level of obesity. Adults experiencing obesity in 2019 spent an average of $1,861 more on medical expenses than people with a healthy weight.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.